French pediatric organizations express concerns over the insufficient reimbursement for Beyfortus, a treatment for bronchiolitis caused by the respiratory syncytial virus. Currently, the treatment is only reimbursed at 30% by Assurance Maladie, leaving families to cover remaining costs, which many cannot afford. The treatment, provided by AstraZeneca and Sanofi, was previously fully funded by the government, leading to a decrease in hospitalizations last year. However, recent evaluations suggest a lack of sufficient evidence regarding its effectiveness in preventing severe cases.

Source